Intensity Therapeutics, Inc. announced on August 12, 2025, that it has regained compliance with The Nasdaq Stock Market LLC's minimum Stockholders' Equity Requirement. The company received a letter from Nasdaq's Listing Qualifications Staff confirming this determination. This follows the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
The company's compliance was based on having at least $2,500,000 in stockholders' equity, a threshold met by combining cash and cash equivalents as of June 30, 2025, with additional cash raised through July 2025. This achievement removes a significant regulatory hurdle for the company.
Lewis H. Bender, President and CEO, stated that the company now projects to have sufficient cash to fund its current operating plan into the second half of 2026. Regaining Nasdaq compliance is a critical step for maintaining the company's listing and investor confidence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.